SEARCH:   Advanced

Blood, 1 December 2004, Vol. 104, No. 12, pp. 3797-3803. Prepublished online as a Blood First Edition Paper on July 27, 2004; DOI 10.1182/blood-2004-01-0231. This Article Full Text (PDF) All Versions of this Article: 2004-01-0231v1 104/12/3797    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Freytes, C. O Articles by van Besien, K. Search for Related Content PubMed PubMed Citation Articles by Freytes, C. O Articles by van Besien, K. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 21, 2004 Accepted July 2, 2004 Myeloablative allogeneic hematopoietic stem cell transplantation in patients who relapse after autologous stem cell transplantation for lymphoma: a report of the international bone marrow transplant registry Cesar O Freytes*, Fausto R Loberiza, J. D Rizzo, Asad Bashey, Christopher N Bredeson, Mitchell S Cairo, Robert P Gale, Mary M Horowitz, Thomas R Klumpp, Rodrigo Martino, Philip L McCarthy, Arturo Molina, Santiago Pavlovsky, Andrew L Pecora, Derek S Serna, Tsuong Tsai, Mei-Jie Zhang, Julie M Vose, Hillard M Lazarus, and Koen van Besien University of Texas Health Science Center, San Antonio, Texas, USA Lymphoma Working Committee of the International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA University of California, San Diego, California, USA Columbia University, New York, New York, USA Center for Advanced Studies in Leukemia, Los Angeles, California, USA University of Pennsylvania, Philadelphia, Pennsylvania, USA Hospital San Creu I Sant Pau, Barcelona, Spain Roswell Park Cancer Institute, Buffalo, New York, USA City of Hope National Medical Center, Duarte, California, USA Fundaleu/ 'Angelica Ocampo', Buenos Aires, Argentina Hackensack University Medical Plaza, Hackensack, New Jersey, USA University of Nebraska Medical Center, Omaha, Nebraska, USA Case Western Reserve University Hospital, Cleveland, Ohio, USA University of Chicago, Chicago, Illinois, USA * Corresponding author; email: freytes{at}uthscsa.edu. Myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly used in patients with lymphoma who relapse after autologous hematopoietic stem cell transplantation (autoHSCT), since the allografts are tumor-free and can potentially induce a graft-versus-tumor effect. We analyzed 114 patients treated with this approach from 1990 to 1999, to assess disease progression, progression-free survival (PFS), and overall survival (OS). Cumulative incidence of disease progression at 3 years was 52% while treatment-related mortality was 22%, lower than previously reported. Three-year probabilities of OS and PFS were 33% and 25%, respectively, but with more prolonged follow-up nearly all patients progressed and five-year probabilities were 24% and 5%, respectively. Complete remission at time of alloHSCT and use of total body irradiation (TBI) in patients with non-Hodgkin lymphoma (NHL) were associated with lower rates of progression and higher OS. In summary, alloHSCT is feasible in patients with lymphoma relapsing after autoHSCT and can result in prolonged survival for some but is usually not curative. Most likely to benefit are patients who have an HLA-matched sibling donor, are in remission, and have a good performance status. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF] M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF] S.-W. Kim, T. E. Tanimoto, N. Hirabayashi, S. Goto, M. Kami, S. Yoshioka, T. Uchida, K. Kishi, Y. Tanaka, A. Kohno, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Blood, July 1, 2006; 108(1): 382 - 389. [Abstract] [Full Text] [PDF] N. L. Bartlett Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy Hematology, January 1, 2005; 2005(1): 245 - 251. [Abstract] [Full Text] [PDF] J. W. Sweetenham Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease Hematology, January 1, 2005; 2005(1): 252 - 259. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020